Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy

Detalhes bibliográficos
Autor(a) principal: Valim, Vanessa de Souza
Data de Publicação: 2014
Outros Autores: Amorin, Bruna, Silva, Annelise Martins Pezzi da, Silva, Maria Aparecida Lima da, Alegretti, Ana Paula, Silla, Lucia Mariano da Rocha
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/131280
Resumo: Mesenchymal stromal cells (MSC) have shown their benefits in graft-versus-host disease (GVHD), with five unsettled matters: 1) MSCs expansion in medium with Fetal Bovine Serum (FBS) and its risk of xenoreaction; 2) The number of cells indicated for therapy that is relatively high, with the need to optimize the expansion, number and time wise; 3) The utilization of third party donors; 4) Culture passage number (P); and 5) Source of the cells. This study was designed to determine the superiority of the Platelet Lysates (PL) over FBS on the expansion of MSC, the optimal cell’ plating density and days between each pass, and to investigate if donor total nucleated cells (TNC) obtained from the washouts of discharged bags and filters of hematopoietic stem cell transplantation (HSCT) can be expanded to be used at clinical grade. TNC were removed, plated and after the first passage were cultivated in different concentrations with FBS or PL, and the number of days to reach 80% of confluence was observed. Next, cultures with the same plating density were fed either with PL or with FBS and after seven days counted to analyze how much they had grown in that period. The proliferation of mesenchymal stromal cells in the presence of PL and SFB was averaged 11.88 and 2.5 times, respectively, in a period of 7 days. The highest concentration of plating cells using PL took less time to reach confluence as compared with the three lower ones. This study suggests that the PL is the best choice as a supplement to expand MSC and to allow the proliferation of enough number of MSC at P2 for clinical use.
id UFRGS-2_2956fb6e757b5c0ffa1b14a4a1a2c6f3
oai_identifier_str oai:www.lume.ufrgs.br:10183/131280
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Valim, Vanessa de SouzaAmorin, BrunaSilva, Annelise Martins Pezzi daSilva, Maria Aparecida Lima daAlegretti, Ana PaulaSilla, Lucia Mariano da Rocha2015-12-23T02:40:23Z20142325-7776http://hdl.handle.net/10183/131280000979659Mesenchymal stromal cells (MSC) have shown their benefits in graft-versus-host disease (GVHD), with five unsettled matters: 1) MSCs expansion in medium with Fetal Bovine Serum (FBS) and its risk of xenoreaction; 2) The number of cells indicated for therapy that is relatively high, with the need to optimize the expansion, number and time wise; 3) The utilization of third party donors; 4) Culture passage number (P); and 5) Source of the cells. This study was designed to determine the superiority of the Platelet Lysates (PL) over FBS on the expansion of MSC, the optimal cell’ plating density and days between each pass, and to investigate if donor total nucleated cells (TNC) obtained from the washouts of discharged bags and filters of hematopoietic stem cell transplantation (HSCT) can be expanded to be used at clinical grade. TNC were removed, plated and after the first passage were cultivated in different concentrations with FBS or PL, and the number of days to reach 80% of confluence was observed. Next, cultures with the same plating density were fed either with PL or with FBS and after seven days counted to analyze how much they had grown in that period. The proliferation of mesenchymal stromal cells in the presence of PL and SFB was averaged 11.88 and 2.5 times, respectively, in a period of 7 days. The highest concentration of plating cells using PL took less time to reach confluence as compared with the three lower ones. This study suggests that the PL is the best choice as a supplement to expand MSC and to allow the proliferation of enough number of MSC at P2 for clinical use.application/pdfengCellBio. Delaware. Vol. 3, no. 1 (Mar. 2014), p. 25-33Terapia baseada em transplante de células e tecidosCélulas-tronco mesenquimaisOptimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapyEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000979659.pdf000979659.pdfTexto completo (inglês)application/pdf726412http://www.lume.ufrgs.br/bitstream/10183/131280/1/000979659.pdfa1f86f80967ead6b5912fc25cff90809MD51TEXT000979659.pdf.txt000979659.pdf.txtExtracted Texttext/plain33819http://www.lume.ufrgs.br/bitstream/10183/131280/2/000979659.pdf.txt8261018a87205932ad30be2cb86291a5MD52THUMBNAIL000979659.pdf.jpg000979659.pdf.jpgGenerated Thumbnailimage/jpeg2025http://www.lume.ufrgs.br/bitstream/10183/131280/3/000979659.pdf.jpgb4b1330c46ca3264b4202036138180d7MD5310183/1312802024-01-06 04:37:22.428066oai:www.lume.ufrgs.br:10183/131280Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2024-01-06T06:37:22Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
title Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
spellingShingle Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
Valim, Vanessa de Souza
Terapia baseada em transplante de células e tecidos
Células-tronco mesenquimais
title_short Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
title_full Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
title_fullStr Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
title_full_unstemmed Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
title_sort Optimization of the cultivation of donor mesenchymal stromal cells for clinical use in cellular therapy
author Valim, Vanessa de Souza
author_facet Valim, Vanessa de Souza
Amorin, Bruna
Silva, Annelise Martins Pezzi da
Silva, Maria Aparecida Lima da
Alegretti, Ana Paula
Silla, Lucia Mariano da Rocha
author_role author
author2 Amorin, Bruna
Silva, Annelise Martins Pezzi da
Silva, Maria Aparecida Lima da
Alegretti, Ana Paula
Silla, Lucia Mariano da Rocha
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Valim, Vanessa de Souza
Amorin, Bruna
Silva, Annelise Martins Pezzi da
Silva, Maria Aparecida Lima da
Alegretti, Ana Paula
Silla, Lucia Mariano da Rocha
dc.subject.por.fl_str_mv Terapia baseada em transplante de células e tecidos
Células-tronco mesenquimais
topic Terapia baseada em transplante de células e tecidos
Células-tronco mesenquimais
description Mesenchymal stromal cells (MSC) have shown their benefits in graft-versus-host disease (GVHD), with five unsettled matters: 1) MSCs expansion in medium with Fetal Bovine Serum (FBS) and its risk of xenoreaction; 2) The number of cells indicated for therapy that is relatively high, with the need to optimize the expansion, number and time wise; 3) The utilization of third party donors; 4) Culture passage number (P); and 5) Source of the cells. This study was designed to determine the superiority of the Platelet Lysates (PL) over FBS on the expansion of MSC, the optimal cell’ plating density and days between each pass, and to investigate if donor total nucleated cells (TNC) obtained from the washouts of discharged bags and filters of hematopoietic stem cell transplantation (HSCT) can be expanded to be used at clinical grade. TNC were removed, plated and after the first passage were cultivated in different concentrations with FBS or PL, and the number of days to reach 80% of confluence was observed. Next, cultures with the same plating density were fed either with PL or with FBS and after seven days counted to analyze how much they had grown in that period. The proliferation of mesenchymal stromal cells in the presence of PL and SFB was averaged 11.88 and 2.5 times, respectively, in a period of 7 days. The highest concentration of plating cells using PL took less time to reach confluence as compared with the three lower ones. This study suggests that the PL is the best choice as a supplement to expand MSC and to allow the proliferation of enough number of MSC at P2 for clinical use.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-12-23T02:40:23Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/131280
dc.identifier.issn.pt_BR.fl_str_mv 2325-7776
dc.identifier.nrb.pt_BR.fl_str_mv 000979659
identifier_str_mv 2325-7776
000979659
url http://hdl.handle.net/10183/131280
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv CellBio. Delaware. Vol. 3, no. 1 (Mar. 2014), p. 25-33
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/131280/1/000979659.pdf
http://www.lume.ufrgs.br/bitstream/10183/131280/2/000979659.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/131280/3/000979659.pdf.jpg
bitstream.checksum.fl_str_mv a1f86f80967ead6b5912fc25cff90809
8261018a87205932ad30be2cb86291a5
b4b1330c46ca3264b4202036138180d7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801224893118808064